Institutional investor / life sciences lender
Appears in 1 story
Holds $350 million non-recourse note secured by YUPELRI cash flows
Zymeworks, a Vancouver biotech built on research partnerships, now owns a commercial medicine. The Sept. 23 closing of its Theravance Biopharma acquisition added YUPELRI, a once-daily nebulized COPD treatment that posted $133.1 million in sales in the first half of 2026, plus the hospital sales team behind it.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
